secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prime Medicine, Inc. (PRME)
CIK:        0001894562
Form:       8-K
Filed at:   2024-02-16T23:59:59+00:00
Accession:  0001193125-24-038016
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prime Medicine prices $150.9M public offering of common stock and pre-funded warrants
--------------------------------------------------------------------------------

- Offering of 19,200,001 shares at $6.25/share plus pre-funded warrants for 3,200,005 shares.
- Net proceeds estimated at approximately $150.9M after underwriting discounts and expenses.
- Proceeds to fund R&D, clinical development, and general corporate purposes.
- Closing expected on or about February 20, 2024, subject to customary conditions.
- Underwriters granted 30-day option to purchase up to an additional 3,360,000 shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894562/000119312524038016/0001193125-24-038016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894562/000119312524038016/d721402d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-038016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer